# Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults

> **NCT01389479** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1000 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Fluviral™
- **BIOLOGICAL:** Fluzone®

## Key facts

- **NCT ID:** NCT01389479
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2005-05
- **Final completion:** 2005-05
- **Target enrollment:** 1000 (ACTUAL)
- **Last updated:** 2017-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01389479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01389479, "Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01389479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*